Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents

Experimental Cell Research

Volumn 318, Issue 9, 2012, Pages 1068-1073

  Tanaka, Tetsuhiro ^a,b   Nangaku, Masaomi ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anemia; Erythropoietin; Erythropoietin receptor; HIF; PHD; Pleiotropic effect

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR; OXYGENASE; RECOMBINANT ERYTHROPOIETIN;

BLOOD CLOT LYSIS; BRAIN PROTECTION; CHRONIC KIDNEY DISEASE; ERYTHROPOIESIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEART PROTECTION; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 84862783287     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.02.035     Document Type: Review

References (51)

1. Miyake T., Kung C.K., Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977, 252(15):5558-5564.
2. Maxwell P.H., Osmond M.K., Pugh C.W., Heryet A., Nicholls L.G., Tan C.C., Doe B.G., Ferguson D.J., Johnson M.H., Ratcliffe P.J. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 1993, 44(5):1149-1162.
3. Semenza G.L., Dureza R.C., Traystman M.D., Gearhart J.D., Antonarakis S.E. Human erythropoietin gene expression in transgenic mice: multiple transcription initiation sites and cis-acting regulatory elements. Mol. Cell. Biol. 1990, 10(3):930-938.
4. Semenza G.L., Koury S.T., Nejfelt M.K., Gearhart J.D., Antonarakis S.E. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(19):8725-8729.
5. Obara N., Suzuki N., Kim K., Nagasawa T., Imagawa S., Yamamoto M. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 2008, 111(10):5223-5232.
6. La Ferla K., Reimann C., Jelkmann W., Hellwig-Burgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J. Off. Publ. Fed Am. Soc. Exp. Biol. 2002, 16(13):1811-1813.
7. Frede S., Freitag P., Geuting L., Konietzny R., Fandrey J. Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 2011, 117(18):4905-4914.
8. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 2006, 17(1):17-25.
9. Scortegagna M., Ding K., Zhang Q., Oktay Y., Bennett M.J., Bennett M., Shelton J.M., Richardson J.A., Moe O., Garcia J.A. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005, 105(8):3133-3140.
10. Warnecke C., Zaborowska Z., Kurreck J., Erdmann V.A., Frei U., Wiesener M., Eckardt K.U. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. Off. Publ. Fed Am. Soc. Exp. Biol. 2004, 18(12):1462-1464.
11. Rosenberger C., Mandriota S., Jurgensen J.S., Wiesener M.S., Horstrup J.H., Frei U., Ratcliffe P.J., Maxwell P.H., Bachmann S., Eckardt K.U. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J. Am. Soc. Nephrol. 2002, 13(7):1721-1732.
12. Percy M.J., Furlow P.W., Lucas G.S., Li X., Lappin T.R., McMullin M.F., Lee F.S. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 2008, 358(2):162-168.
13. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30(4):393-402.
14. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003, 22(16):4082-4090.
15. Minamishima Y.A., Moslehi J., Bardeesy N., Cullen D., Bronson R.T., Kaelin W.G. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008, 111(6):3236-3244.
16. Percy M.J., Zhao Q., Flores A., Harrison C., Lappin T.R., Maxwell P.H., McMullin M.F., Lee F.S. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(3):654-659.
17. Bernhardt W.M., Wiesener M.S., Scigalla P., Chou J., Schmieder R.E., Gunzler V., Eckardt K.U. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol. 2010, 21(12):2151-2156.
18. Chiang C.K., Tanaka T., Inagi R., Fujita T., Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Laboratory investigation 2011, 91(11):1564-1571.
19. Elliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., Spahr C., Um M., Van G., Begley C.G. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006, 107(5):1892-1895.
20. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 2002, 8(8):495-505.
21. Ehrenreich H., Weissenborn K., Prange H., Schneider D., Weimar C., Wartenberg K., Schellinger P.D., Bohn M., Becker H., Wegrzyn M., Jahnig P., Herrmann M., Knauth M., Bahr M., Heide W., Wagner A., Schwab S., Reichmann H., Schwendemann G., Dengler R., Kastrup A., Bartels C. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. J. Cereb. Circ. 2009, 40(12):e647-e656.
22. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., Thompson R.B., Petrofski J.A., Annex B.H., Stamler J.S., Koch W.J. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003, 112(7):999-1007.
23. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A.M., Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102(4):1340-1346.
24. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami A., Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305(5681):239-242.
25. Fiordaliso F., Chimenti S., Staszewsky L., Bai A., Carlo E., Cuccovillo I., Doni M., Mengozzi M., Tonelli R., Ghezzi P., Coleman T., Brines M., Cerami A., Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(6):2046-2051.
26. Erbayraktar S., Grasso G., Sfacteria A., Xie Q.W., Coleman T., Kreilgaard M., Torup L., Sager T., Erbayraktar Z., Gokmen N., Yilmaz O., Ghezzi P., Villa P., Fratelli M., Casagrande S., Leist M., Helboe L., Gerwein J., Christensen S., Geist M.A., Pedersen L.O., Cerami-Hand C., Wuerth J.P., Cerami A., Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(11):6741-6746.
27. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.W., Smart J., Su-Rick C.J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(41):14907-14912.
28. Um M., Gross A.W., Lodish H.F. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell. Signal. 2007, 19(3):634-645.
29. Brines M., Patel N.S., Villa P., Brines C., Mennini T., De Paola M., Erbayraktar Z., Erbayraktar S., Sepodes B., Thiemermann C., Ghezzi P., Yamin M., Hand C.C., Xie Q.W., Coleman T., Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(31):10925-10930.
30. Patel N.S., Nandra K.K., Brines M., Collino M., Wong W.S., Kapoor A., Benetti E., Goh F.Y., Fantozzi R., Cerami A., Thiemermann C. A non-erythropoietic peptide that mimicks the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol. Med. 2011.
31. Yang C.W., Li C., Jung J.Y., Shin S.J., Choi B.S., Lim S.W., Sun B.K., Kim Y.S., Kim J., Chang Y.S., Bang B.K. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. Off. Publ. Fed Am. Soc. Exp. Biol. 2003, 17(12):1754-1755.
32. Vesey D.A., Cheung C., Pat B., Endre Z., Gobe G., Johnson D.W. Erythropoietin protects against ischaemic acute renal injury. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. 2004, 19(2):348-355.
33. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., Kieswich J., Allen D., Harwood S., Raftery M., Thiemermann C., Yaqoob M.M. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J. Am. Soc. Nephrol. 2004, 15(8):2115-2124.
34. Vaziri N.D., Zhou X.J., Liao S.Y. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am. J. Physiol. 1994, 266(3 Pt 2):F360-F366.
35. Ishii Y., Sawada T., Murakami T., Sakuraoka Y., Shiraki T., Shimizu A., Kubota K., Fuchinoue S., Teraoka S. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. 2011, 26(4):1157-1162.
36. Endre Z.H., Walker R.J., Pickering J.W., Shaw G.M., Frampton C.M., Henderson S.J., Hutchison R., Mehrtens J.E., Robinson J.M., Schollum J.B., Westhuyzen J., Celi L.A., McGinley R.J., Campbell I.J., George P.M. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int. 2010, 77(11):1020-1030.
37. Menne J., Park J.K., Shushakova N., Mengel M., Meier M., Fliser D. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J. Am. Soc. Nephrol. 2007, 18(7):2046-2053.
38. Eto N., Wada T., Inagi R., Takano H., Shimizu A., Kato H., Kurihara H., Kawachi H., Shankland S.J., Fujita T., Nangaku M. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007, 72(4):455-463.
39. Logar C.M., Brinkkoetter P.T., Krofft R.D., Pippin J.W., Shankland S.J. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int. 2007, 72(4):489-498.
40. Katavetin P., Inagi R., Miyata T., Shao J., Sassa R., Adler S., Eto N., Kato H., Fujita T., Nangaku M. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem. Biophys. Res. Commun. 2007, 359(4):928-934.
41. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., Kirsch T., de Groot K., Laudeley R., Niemczyk E., Guler F., Menne J., Haller H., Fliser D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004, 110(8):1006-1012.
42. Gouva C., Nikolopoulos P., Ioannidis J.P., Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004, 66(2):753-760.
43. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006, 355(20):2071-2084.
44. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006, 355(20):2085-2098.
45. Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., Feyzi J.M., Ivanovich P., Kewalramani R., Levey A.S., Lewis E.F., McGill J.B., McMurray J.J., Parfrey P., Parving H.H., Remuzzi G., Singh A.K., Solomon S.D., Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2009, 361(21):2019-2032.
46. Stohlawetz P.J., Dzirlo L., Hergovich N., Lackner E., Mensik C., Eichler H.G., Kabrna E., Geissler K., Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000, 95(9):2983-2989.
47. Szczech L.A., Barnhart H.X., Inrig J.K., Reddan D.N., Sapp S., Califf R.M., Patel U.D., Singh A.K. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008, 74(6):791-798.
48. Solomon S.D., Uno H., Lewis E.F., Eckardt K.U., Lin J., Burdmann E.A., de Zeeuw D., Ivanovich P., Levey A.S., Parfrey P., Remuzzi G., Singh A.K., Toto R., Huang F., Rossert J., McMurray J.J., Pfeffer M.A. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N. Engl. J. Med. 2010, 363(12):1146-1155.
49. Coleman T.R., Westenfelder C., Togel F.E., Yang Y., Hu Z., Swenson L., Leuvenink H.G., Ploeg R.J., d'Uscio L.V., Katusic Z.S., Ghezzi P., Zanetti A., Kaushansky K., Fox N.E., Cerami A., Brines M. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(15):5965-5970.
50. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., Zwahlen M., Clarke M., Weingart O., Kluge S., Piper M., Rades D., Steensma D.P., Djulbegovic B., Fey M.F., Ray-Coquard I., Machtay M., Moebus V., Thomas G., Untch M., Schumacher M., Egger M., Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373(9674):1532-1542.
51. Rizzo J.D., Somerfield M.R., Hagerty K.L., Seidenfeld J., Bohlius J., Bennett C.L., Cella D.F., Djulbegovic B., Goode M.J., Jakubowski A.A., Rarick M.U., Regan D.H., Lichtin A.E. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008, 111(1):25-41.